This review is a summary of an individual study; reversal effects of idarucizumab on active dabigatran (RE-VERSE AD) study. With these NOAC reversal agents and studies highly anticipated, this study is worth some extra attention.
Independent commentary is provided by Associate Professor John Amerena, a Cardiologist at Barwon Health with a joint appointment in the Department of Clinical and Biomedical Sciences at the University of Melbourne and the Department of Epidemiology and Preventive Medicine at Monash University. He is also Director of the Heart Failure Programme at Barwon Health.
Please login below to download this issue (PDF)